期刊文献+
共找到147篇文章
< 1 2 8 >
每页显示 20 50 100
Implantation of Radioactive ^(125)I Seeds Improves the Prognosis of Locally Advanced Pancreatic Cancer Patients:A Retrospective Study 被引量:12
1
作者 李永峰 刘志强 +4 位作者 张禹舜 董黎明 王春友 勾善淼 吴河水 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2016年第2期205-210,共6页
Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from 125 ^I seed implantation. This re... Locally advanced pancreatic cancer is associated with a very poor prognosis. This study was performed to evaluate whether patients with locally advanced pancreatic cancer benefit from 125 ^I seed implantation. This retrospective study included 224 patients with locally advanced pancreatic cancer, with 137 patients(61.2%) in the implantation(IP) group and 87(38.9%) in the non-implantation(NIP) group. The survival status, complications and objective curative effects were compared between the groups. The average operative time in the IP group was significantly longer than that in the NIP group(243±51 vs. 214±77 min). The tumor response rates were 9.5% and 0 at the 2nd month after surgery in the IP and NIP groups, respectively(P〈0.05). The IP group exhibited a trend toward pain relief at the 6th month after surgery. The global health status scores of the IP group were higher than those of the NIP group at the 3rd and 6th month after surgery. The median survival time in the IP group was significantly longer than that in the NIP group. In conclusion, patients with locally advanced pancreatic cancer can benefit from 125 I seed implantation in terms of local tumor control, survival time, pain relief and quality of life. 展开更多
关键词 125I seed implantation locally advanced pancreatic cancer pain relief quality of life
下载PDF
A pilot study on combination of cryosurgery and ^(125)iodine seed implantation for treatment of locally advanced pancreatic cancer 被引量:38
2
作者 Ke-Cheng Xu Li-Zhi Niu +4 位作者 Yi-Ze Hu Wei-Bing He Yi-Song He Ying-Fei Li Jian-Sheng Zuo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第10期1603-1611,共9页
AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, ... AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, females 13), with a median age of 59 years, were enrolled in the study. Twelve patients had liver metastases. In all cases the tumors were considered unresectable after a comprehensive evaluation. Patients were treated with cryosurgery, which was performed intraoperatively or percutaneously unde guidance of ultrasound and/or computed tomography (CT), and 125iodine seed implantation, which was performed during cryosurgery or post-cryosurgery under guidance of ultrasound and/or CT. A few patients received regional celiac artery chemotherapy. RESULTS: Thirteen patients received intraoperative cryosurgery and 36 received percutaneous cryosurgery Some patients underwent repeat cryosurgery. 125Iodine seed implantation was performed during freezing procedure in 35 patients and 3-9 d after cryosurgery in 14 cases. Twenty patients, 10 of whom had hepaticmetastases received regional chemotherapy. At 3 mo after therapy, CT was repeated to estimate tumor response to therapy. Most patients showed varying degrees of tumor necrosis. Complete response (CR) of tumor was seen in 20.4% patients, partial response (PR), in 38.8%, stable disease (SD), in 30.6%, and progressive disease (PD), in 10.2%. Adverse effects associated with cryosurgery included upper abdomen pain and increased serum amylase. Acute pancreatitis was seen in 6 patients one of whom developed severe pancreatitis. All adverse effects were controlled by medical management with no poor outcome. There was no therapy-related mortality. During a median follow-up of 18 mo (range of 5-40), the median survival was 16.2 mo, with 26 patients (53.1%) surviving for 12 mo or more. Overall, the 6-, 12-, 24- and 36-mo survival rates were 94.9%, 63.1%, 22.8% and 9.5%, respectively. Eight patients had survival of 24 mo or more. The patient with the longest survival (40 mo) is still living without evidence of tumor recurrence. CONCLUSION: Cryosurgery, which is far less invasive than conventional pancreatic resection, and is associated with a low rate of adverse effects, should be the treatment of choice for patients with locally advanced pancreatic cancer. 125Iodine seed implantation can destroy the residual surviving cancer cells after cryosurgery. Hence, a combination of both modalities has a complementary effect. 展开更多
关键词 Pancreatic cancer CRYOSURGERY CRYOABLATION ^^125Iodine seed implantation
下载PDF
Intraoperative radiofrequency ablation combined with ^(125)iodine seed implantation for unresectable pancreatic cancer 被引量:22
3
作者 Yi-Ping Zou Wei-Min Li +4 位作者 Fang Zheng Fu-Cheng Li Hui Huang Ji-Dong Du Hao-Run Liu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第40期5104-5110,共7页
AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with 125 iodine seed implantation for unresectable pancreatic cancer. METHODS: Thirty-two patients (21 mal... AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with 125 iodine seed implantation for unresectable pancreatic cancer. METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study. The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation. Diagnosis of pancreatic cancer was made through intraoperative biopsy. Patients were treated with FRA combined with 125 iodine seed implantation. In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a 125 iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.RESULTS: The serum CA 19-9 level was decreased from 512 ± 86 U/mL before operation to 176 ± 64 U/mL, 108 ± 42 U/mL and 114 ± 48 U/mL, respectively, 1, 3 and 6 mo after operation (P < 0.05). The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05). The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo. The median survival time of patients at stage Ⅲ was longer than that of those at stage Ⅳ (19 mo vs 10 mo, P = 0.0026). The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176). Of the 32 patients, 3 (10.6%) experienced postoperative complications including transient biliary leaks in 2 patients and acute pancreatitis in 1 patient. All the patients recovered well after conservative support treatment. CONCLUSION: Intraoperative RFA combined with 125 iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage Ⅲ. 展开更多
关键词 Unresectable pancreatic cancer Radiofrequency ablation 125 iodine seed implantation
下载PDF
Radioactive ^125I seed implantation for locally advanced pancreatic cancer:A retrospective analysis of 50 cases 被引量:7
4
作者 Cheng-Gang Li Zhi-Peng Zhou +2 位作者 Yu-Ze Jia Xiang-Long Tan Yu-Yao Song 《World Journal of Clinical Cases》 SCIE 2020年第17期3743-3750,共8页
BACKGROUND Pancreatic cancer is one of the common malignant tumors of the digestive system,and radical resection is the first choice of treatment for pancreatic cancer.If patients with locally advanced pancreatic canc... BACKGROUND Pancreatic cancer is one of the common malignant tumors of the digestive system,and radical resection is the first choice of treatment for pancreatic cancer.If patients with locally advanced pancreatic cancer cannot be treated in time and effectively,their disease often develops rapidly and their survival period is very short.AIM To evaluate the therapeutic effect of ^125I seed implantation in patients with locally advanced pancreatic cancer.METHODS The demographics and perioperative outcomes of a consecutive series of patients who underwent ^125I seed implantation to treat locally advanced pancreatic cancer between January 1,2017 and June 30,2019 were retrospectively analyzed.According to the results of preoperative computed tomography or magnetic resonance imaging,the treatment planning system was used to determine the area and number of ^125I seeds implanted.During the operation,^125I seeds were implanted into the tumor under the guidance of intraoperative ultrasound,with a spacing of 1.5 cm and a row spacing of 1.5 cm.For patients with obstructive jaundice and digestive tract obstruction,choledochojejunostomy and gastroenterostomy were performed simultaneously.After operation,the patients were divided into a non-chemotherapy group and a chemotherapy group that received gemcitabine combined with albumin-bound paclitaxel treatment.RESULTS Among the 50 patients,there were 29 males and 21 females,with a mean age of 56.9±9.8 years.The main reason for the failure of radical resection was superior mesenteric artery invasion(37,74%),followed by superior mesenteric vein invasion(33,66%).Twenty-one(62%)patients underwent palliative surgery and postoperative pain relief occurred in 40(80%)patients.The estimated blood loss in operation was 107.4±115.3 mL and none of the patient received blood transfusion.The postoperative hospital stay was 7.5±4.2 d;one patient had biliary fistula and three had pancreatic fistula,all of whom recovered after conservative treatment.After operation,26 patients received chemotherapy and 24 did not.The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not(60.7%vs 35.9%,P=0.034).The mean overall survival of patients of the chemotherapy group and nonchemotherapy group was 14 and 11 mo,respectively(χ^2=3.970,P=0.046).CONCLUSION Radioactive ^125I seed implantation combined with postoperative chemotherapy can prolong the survival time,relieve pain,and improve the quality of life of patients with locally advanced pancreatic cancer. 展开更多
关键词 Pancreatic cancer ^Radioactive^125I seeds RADIOTHERAPY Permanent implantation
下载PDF
DTI and pathological changes in a rabbit model of radiation injury to the spinal cord after ^(125)I radioactive seed implantation 被引量:4
5
作者 Xia Cao Le Fang +2 位作者 Chuan-yu Cui Shi Gao Tian-wei Wang 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第3期528-535,共8页
Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological ch... Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological changes and thus may be used for the evaluation of spinal cord injuries caused by radiation therapy. Radioactive ^125I seeds to irradiate 90% of the spinal cord tissue at doses of 40–100 Gy (D90) were implanted in rabbits at T10 to induce radiation injury, and we evaluated their safety for use in the spinal cord. Diffusion tensor imaging showed that with increased D90, the apparent diffusion coefficient and fractional anisotropy values were increased. Moreover, pathological damage of neurons and microvessels in the gray matter and white matter was aggravated. At 2 months after implantation, obvious pathological injury was visible in the spinal cords of each group. Magnetic resonance diffusion tensor imaging revealed the radiation injury to the spinal cord, and we quantified the degree of spinal cord injury through apparent diffusion coefficient and fractional anisotropy. 展开更多
关键词 nerve regeneration BRACHYTHERAPY ^^125I radioactive seeds magnetic resonance imaging radiation injury of the spinal cord diffusion tensor imaging apparent diffusion coefficient fractional anisotropy neural regeneration
下载PDF
Dosimetry for ^(125) I radioactive seed implantation therapy for hepatocellular carcinoma 被引量:3
6
作者 Jin Lue Xiufeng Cao 《Journal of Nanjing Medical University》 2008年第5期269-272,共4页
Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. Exter... Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious. In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially ^125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local "conformal radiotherapy" and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn' t yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for ^125I interstitial implantation brachytherapy for HCC. 展开更多
关键词 carcinoma hepatocellular/radiotherapy BRACHYTHERAPY radioactive seeds ^^125I
下载PDF
Relationship between miR-7-5p expression and ^(125)I seed implantation efficacy in pancreatic cancer and functional analysis of target genes 被引量:1
7
作者 Tingting Hao Chaoqi Wang +3 位作者 Yingjie Song Wanyan Wu Xuetao Li Tao Fan 《Oncology and Translational Medicine》 CAS 2021年第4期177-182,共6页
Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.... Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.Methods Thirty-seven patients with unresectable pancreatic ductal adenocarcinoma(PDAC)treated with radioactive ^(125)I seed implantation were enrolled.RT-PCR was used to detect the expression level of miR-7-5p in cancer tissues and analyze the relationship between miR-7-5p expression and ^(125)I radiation sensitivity.Bioinformatic software and online tools were used to predict the miR-7-5p target genes and analyze their functional annotation and pathway enrichment.Results Radioactive ^(125)I seed implantation was followed up for 2 months.The objective response rate of the miR-7-5p high expression group was 65.0%(13/20),whereas the objective response rate of the miR-7-5p low expression group was 5.88%(1/17),and the difference between the two groups was statistically significant(χ^(2)=13.654,P<0.001).A total of 187 target genes were predicted using three databases.GO functional annotation showed that target genes were mainly involved in cellular response to insulin stimulus,regulation of gene expression by genetic imprinting,cytosol,peptidyl-serine phosphorylation,bHLH transcription factor binding,cargo loading into vesicles,cellular response to epinephrine stimulus,and nucleoplasm.KEGG pathway enrichment analysis showed that target genes were mainly involved in the ErbB signaling pathway,HIF-1 signaling pathway,axon guidance,longevity regulatory pathway,endocrine resistance,glioma,choline metabolism in cancer,and EGFR tyrosine kinase inhibitor drug resistance.Molecular complex detection analysis by Cytoscape revealed that PIGH,RAF1,EGFR,NXT2,PIK3CD,PIK3R3,ERBB4,TRMT13,and C5orf22 were the key modules of miR-7-5p target gene clustering.Conclusion The expression of miR-7-5p in pancreatic cancer tissues positively correlated with the radiosensitivity of ^(125)I seeds.Via targeted gene regulation,miR-7-5p acts on the network of multiple signaling pathways in PDAC and participates in its occurrence and development.Thus,miR-7-5p may become a predictive index of ^(125)I seed implantation therapy sensitivity in PDAC patients. 展开更多
关键词 miR-7-5p pancreatic cancer ^^(125)I radioactive seed implantation
下载PDF
Radioactive 125I seed implantation for pancreatic cancer with unexpected liver metastasis:A preliminary experience with 26 patients 被引量:5
8
作者 Cheng-Gang Li Zhi-Peng Zhou +2 位作者 Yu-Ze Jia Xiang-Long Tan Yu-Yao Song 《World Journal of Clinical Cases》 SCIE 2021年第4期792-800,共9页
BACKGROUND Preoperative diagnosis rate of pancreatic cancer has increased year by year.The prognosis of pancreatic cancer patients with unexpected liver metastasis found by intraoperative exploration is very poor,and ... BACKGROUND Preoperative diagnosis rate of pancreatic cancer has increased year by year.The prognosis of pancreatic cancer patients with unexpected liver metastasis found by intraoperative exploration is very poor,and there is no effective and unified treatment strategy.AIM To evaluate the therapeutic effect of radioactive 125I seed implantation for pancreatic cancer patients with unexpected liver metastasis.METHODS The demographics and perioperative outcomes of patients who underwent 125I seed implantation to treat pancreatic cancer with unexpected liver metastasis between January 1,2017 and June 1,2019 were retrospectively analyzed.During the operation,125I seeds were implanted into the pancreatic tumor under the guidance of intraoperative ultrasound,with a spacing of 1.5 cm and a row spacing of 1.5 cm.For patients with obstructive jaundice and digestive tract obstruction,choledochojejunostomy and gastroenterostomy were performed simultaneously.After operation,the patients were divided into a non-chemotherapy group and a chemotherapy group that received gemcitabine combined with albumin-bound paclitaxel treatment.RESULTS Preoperative imaging evaluation of all patients in this study showed that the tumor was resectable without liver metastasis.There were 26 patients in this study,including 18 males and 8 females,aged 60.5±9.7 years.The most common tumor site was the pancreatic head(17,65.4%),followed by the pancreatic neck and body(6,23.2%)and pancreatic tail(3,11.4%).Fourteen patients(53.8%)underwent palliative surgery and postoperative pain relief occurred in 22 patients(84.6%).The estimated blood loss in operation was 148.3±282.1 mL and one patient received blood transfusion.The postoperative hospital stay was 7.6±2.8 d.One patient had biliary fistula,one had pancreatic fistula,and all recovered after conservative treatment.After operation,7 patients received chemotherapy and 19 did not.The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not(68.6%vs 15.8%,P=0.012).The mean overall survival of patients in the chemotherapy group and non-chemotherapy group was 16.3 mo and 10 mo,respectively(χ2=7.083,P=0.008).CONCLUSION Radioactive 125I seed implantation combined with postoperative chemotherapy can prolong the survival time and relieve pain of pancreatic cancer patients with unexpected liver metastasis. 展开更多
关键词 Pancreatic cancer Liver metastases Radioactive 125I seeds RADIOTHERAPY Permanent implantation Therapeutic effect
下载PDF
Intraoperative permanent implantation of radioactive I-125 seed for local advanced non small lung cancer 被引量:1
9
作者 Dekang Yang Yuan Qiu +3 位作者 Dong Li Xiangyang Cheng Jianxing He Ping Chen 《The Chinese-German Journal of Clinical Oncology》 CAS 2007年第2期191-192,共2页
Objective: To study the clinical efficacy and methods of permanent implantation of radioactive I-125 seed in surgery for local advanced non small lung cancer (LANSCLC). Methods: From Apr. 2004 to Apr. 2006, the I-... Objective: To study the clinical efficacy and methods of permanent implantation of radioactive I-125 seed in surgery for local advanced non small lung cancer (LANSCLC). Methods: From Apr. 2004 to Apr. 2006, the I-125 seeds were implanted into 30 patients with LANSCLC in surgery. The numbers of seeds were 10-40. The chemotherapy was performed in 10 to 14 days after operation. Results: There was no operative death, and the distribution of seeds and complications were reviewed by CT and X-ray after treatment. The distribution of seeds was satisfactory in all patients. The complete response rate (CR) was 56.6% and the part response (PR) was 26.6%. The overall response rate was 83.3% after 4-24 months of surgery. There was no one occurred radiation pneumonia. Prospective efficacy await further follow-up. Conclusion: Permanent implantation of 1-125 seed in surgery for LANSCLC, is a safe and effective method with mild complications. 展开更多
关键词 local advanced non small lung cancer radioactive I-125 seed implantation
下载PDF
^(125)I粒子植入在难治性甲状腺癌治疗中的应用价值
10
作者 龚成鹏 张雅婧 +1 位作者 胡胜清 高再荣 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2024年第2期269-274,共6页
作为近距离放射治疗的一种,^(125)I粒子植入已广泛应用于各种不可切除或局部复发的恶性肿瘤治疗中,均展现出良好的治疗效果与前景。由于具有疗效确切、安全微创的特点,^(125)I粒子植入为不能再次手术、^(131)I治疗不可控及不适合靶向治... 作为近距离放射治疗的一种,^(125)I粒子植入已广泛应用于各种不可切除或局部复发的恶性肿瘤治疗中,均展现出良好的治疗效果与前景。由于具有疗效确切、安全微创的特点,^(125)I粒子植入为不能再次手术、^(131)I治疗不可控及不适合靶向治疗的持续或复发甲状腺癌提供了一种可选择的手段。该文将简要介绍^(125)I粒子植入在难治性甲状腺癌局部复发灶及其转移灶治疗和病灶术前定位中的应用。 展开更多
关键词 ^^(125)I粒子植入 难治性甲状腺癌 近距离放射治疗
下载PDF
赋能管理模式在^(125)I粒子植入术后放射防护中的效果研究 被引量:1
11
作者 刘丽 黄祥忠 +1 位作者 高福磊 朱翠芳 《介入放射学杂志》 CSCD 北大核心 2024年第1期82-85,共4页
目的探讨赋能管理模式在^(125)I粒子植入术后放射防护中的作用。方法选择医院2020年10月至2022年10月首次进行^(125)I粒子植入的患者66例,随机分为对照组和实验组,对照组(n=33)实施传统健康教育;实验组(n=33)在传统健康教育的基础上实... 目的探讨赋能管理模式在^(125)I粒子植入术后放射防护中的作用。方法选择医院2020年10月至2022年10月首次进行^(125)I粒子植入的患者66例,随机分为对照组和实验组,对照组(n=33)实施传统健康教育;实验组(n=33)在传统健康教育的基础上实施赋能管理模式,评价两组患者在自我效能感、健康教育效果及防护依从性等方面的差异。结果实验组患者在自我效能感、健康教育效果及防护依从性等方面均高于对照组,差异有统计学意义(P<0.05)。结论运用赋能管理模式实施健康教育,能够提高^(125)I粒子植入术后健康教育效果,从而让患者更正确地认识^(125)I粒子治疗,使自我效能感加强,有利于提高术后防护依从性,保护周围人群的安全,值得临床推广。 展开更多
关键词 赋能管理 ^^(125)I粒子植入 放射防护 延续护理
下载PDF
Similar therapeutic effects of ^(125I) seed radiotherapy andγ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma 被引量:5
12
作者 Rui Liu Ji-Tong Shi +4 位作者 Xin Ge Ben-Tao Yang Hong Zhang Jing-Xue Zhang Jian-Min Ma 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2021年第4期547-553,共7页
AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy... AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy.METHODS:In this retrospective comparative case series,the clinical records of 27 primary and 8 recurrent patients were reviewed.Univariate and multivariate analyses were used to identify risk factors associated with distant metastasis(DM),and the overall survival(OS)after the initial surgery was analyzed.RESULTS:The median follow-up after radiotherapy was 36 mo(range 6-120 mo).At the last follow-up after radiotherapy,26(74.3%)patients had no evidence of disease,7(20%)patients had DM,2(5.9%)patients died of DM,and 1 patient with DM was lost to follow-up.Univariate analyses showed that duration of symptoms,bone destruction,T stage classification,and wide excision surgery were risk factors influencing DM(P<0.05).The 5-year and 10-year OS rates after the initial surgery were 95.8%and 79.9%,respectively.The 5-year DM-free survival and disease-free survival rates after radiotherapy were 66.4%and 52.7%,respectively.CONCLUSION:^(125I)seed radiotherapy and local externalγ-ray radiotherapy may have similar therapeutic effects in preventing DM.Patients with T1/T2 stage disease have a better prognosis than those with T3/T4 stage disease. 展开更多
关键词 adenoid cystic carcinoma lacrimal gland ^^(125I)seed radiotherapy γ-ray radiotherapy surgical excision
下载PDF
上海市^(125)I粒子植入治疗技术质量控制研究现状
13
作者 单凤玲 楼菁菁 +1 位作者 张锦明 刘兴党 《肿瘤影像学》 2024年第4期384-387,共4页
目的:分析探讨2022年上海市开展^(125)I粒子植入治疗技术的各医疗中心质量控制现状。方法:根据上海市核医学质量控制中心^(125)I粒子植入治疗技术评估表,对上海市16家医疗机构的20个相关科室的质量控制数据进行分析。结果:对医疗机构基... 目的:分析探讨2022年上海市开展^(125)I粒子植入治疗技术的各医疗中心质量控制现状。方法:根据上海市核医学质量控制中心^(125)I粒子植入治疗技术评估表,对上海市16家医疗机构的20个相关科室的质量控制数据进行分析。结果:对医疗机构基本要求、人员基本要求、技术管理基本要求评估的36项质控内容中,最高符合率为100.00%(36/36),最低符合率为83.33%(30/36),同一家医院不同科室的管理和质量情况也有所不同;对于有关质控各项指标,植入指征正确率(平均)为98.75%,术前制订治疗计划率(平均)为94.74%,粒子活度复测率(平均)为25.13%,术后放射剂量验证率(平均)为83.81%,30 d内穿刺相关主要并发症发生率(平均)为5.67%,30 d内放射性损伤相关主要并发症发生率(平均)为0.85%,粒子植入治疗有效率(平均)为92.2%,30 d内全因死亡率(平均)为0.87%。2个月、4个月、6个月及1年的(平均)随访率分别为97.24%、91.9%、85.31%及71.91%,2个月、4个月、6个月及1年的(平均)生存率分别为96.81%、89.74%、81.31%及66.07%。结论:2022年上海市各医疗中心在^(125)I粒子植入治疗技术的质量控制中仍存在许多问题,各医疗中心应引起重视,按照上海市核医学质量控制中心^(125)I粒子植入治疗技术评估表的要求,完善科室规章制度,完全按照诊疗规范开展该项技术。 展开更多
关键词 ^^(125)I粒子植入 质量控制 核医学
下载PDF
超声引导下放射性^(125)I粒子植入治疗转移性腹膜后去分化脂肪肉瘤1例
14
作者 杨天姿 张秉宜 +1 位作者 刘捷 李兴昶 《中国医药科学》 2024年第4期196-198,共3页
去分化脂肪肉瘤(DDLPS)是一种罕见的脂肪肉瘤亚型,预后不良。本病例报告描述了1例65岁中国女性的肝脏及腹膜后DDLPS,临床表现为无痛性腹部肿物。进行计算机断层扫描和超声检查发现瘤体较大且出现部分脏器转移,遂行腹膜后巨大肿瘤切除术... 去分化脂肪肉瘤(DDLPS)是一种罕见的脂肪肉瘤亚型,预后不良。本病例报告描述了1例65岁中国女性的肝脏及腹膜后DDLPS,临床表现为无痛性腹部肿物。进行计算机断层扫描和超声检查发现瘤体较大且出现部分脏器转移,遂行腹膜后巨大肿瘤切除术及肝部分切除术。术后肿瘤免疫组织化学表现为S-100(+),SOX10(-),Desmin(+)。患者愈合良好,为控制转移病灶,术后三个月行超声引导下右侧腹膜后(肝肾间隙)肿瘤放射性^(125)I粒子植入治疗。通过粒子放射治疗,达到稳定病情的治疗目标。本病例报告对该患者的治疗及病例资料进行分析,从DDLPS的临床诊断、治疗和病理特点等方面对文献进行综述,以期提高诊疗水平。 展开更多
关键词 去分化脂肪肉瘤 转移性 放射性粒子 ^^(125)I 超声 植入治疗
下载PDF
Prospective Clinical Study of <sup>125</sup>I Particle Permanent Implantation for Prostate Cancer
15
作者 Yupeng Xin Daoling Guo +3 位作者 Jiagao Qi Zhengguo Chen Honggang Shao Guangya Yuan 《Open Journal of Urology》 2020年第3期52-59,共8页
Objective: To investigate the clinical effect of 125I radioactive seed implantation and the treatment of prostate cancer with radical resection of prostate cancer. Methods: Within the period of the second phase, 62 ca... Objective: To investigate the clinical effect of 125I radioactive seed implantation and the treatment of prostate cancer with radical resection of prostate cancer. Methods: Within the period of the second phase, 62 cases of prostate cancer patients, aged from 46 to 87 years old, average 69 years old. In the treatment group, 30 cases were implanted with 125I radioactive particles via the rectum with the guidance of the rectum. 32 cases in the control group underwent radical prostatectomy. Results: All patients were operated successfully, the patients were followed up for 12 to 36 months. In the treatment group, the average particle size was 38 + 15. No serious complications caused by rectal puncture. 2 patients occurred 6 months after PSA increased significantly, systemic examination revealed bone metastases, and underwent endocrine therapy. In the control group, there were 2 cases of patients with PSA significantly increased in 5 months after surgery, and the external irradiation plus endocrine therapy. During the observation period, the survival rate of the patients who were implanted with 125I particles in the treatment group without progression was 93.3%. Control group, the cumulative PSA progression free survival rate was 93.7%. Conclusion: Patients with prostate cancer during the second phase, the clinical curative effect of the treatment of prostate cancer with the treatment of 125I of prostate cancer and the treatment of prostate cancer by using radical resection of prostate cancer are quite. This technology has the advantages of small trauma, quick recovery, low damage to normal tissue. 展开更多
关键词 TRANSRECTAL 125I seeds implantation PROSTATE Cancer Internal-Radiation Therapy TRANSRECTAL ULTRASONOGRAPHY
下载PDF
^(125)I粒子永久性植入组织间放射治疗肝癌 被引量:44
16
作者 罗开元 郑江华 +4 位作者 李波 邵庆华 杨国凯 赵泉 杨嵘 《肝胆胰外科杂志》 CAS 2004年第1期29-31,共3页
目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结... 目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结果 :术前、术后 1w及 3个月内血象虽有显著差异 ,但均在正常范围内 ,免疫指标前后变化无统计学意义。A组 :12个月、2 4个月、36个月局部复发率分别为 4 1.7%、5 0 .0 %和 5 9.5 % ;12个月、2 4个月、36个月局部生存率分别为 81.3%、6 3.4 %和 4 7.6 %。B组 :12个月、2 4个月、36个月局部复发率分别为 0、6 .7%和 11.9% ;生存率分别为 94 .7%、87.5 %和 78.4 % ,两组的局部复发率及生存率有显著性差异 (P <0 .0 5 )。结论 :12 5I组织间放射治疗肝癌方法简单、安全 ,近期疗效确切 ,是治疗癌症的理想方法之一。 展开更多
关键词 组织间放疗 ^^125 I粒子 植入 肝肿瘤
下载PDF
经皮穿刺^(125)I粒子植入治疗胃肠道来源肺转移瘤的短期疗效观察 被引量:10
17
作者 周琨 吴沛宏 +4 位作者 张福君 黄金华 范卫君 张亮 刘健 《介入放射学杂志》 CSCD 2006年第4期235-237,共3页
目的评价胃肠道来源肺转移瘤CT导向下125I粒子植入治疗的短期疗效。方法20例胃肠道来源肺转移瘤患者,肺内病灶5个以下,总计病灶数56个,平均每例2.8个病灶,病灶平均直径2.1cm(0.5~3cm)。其中单肺转移13例,双肺7例。原发病灶均有病理诊断... 目的评价胃肠道来源肺转移瘤CT导向下125I粒子植入治疗的短期疗效。方法20例胃肠道来源肺转移瘤患者,肺内病灶5个以下,总计病灶数56个,平均每例2.8个病灶,病灶平均直径2.1cm(0.5~3cm)。其中单肺转移13例,双肺7例。原发病灶均有病理诊断,肺转移均经CT或MRI检查后临床诊断。利用计算机三维立体定向治疗计划系统(TPS)计算布源,在CT引导下将125I粒子植入肺转移病灶内。观察治疗后2个月病灶变化。结果20例56个病灶,完全缓解(CR)32个;部分缓解(PR)19个;无变化(NC)5个。总有效率91.1%。2个月内无死亡病例。发生气胸2例,咯血痰2例,胸腔出血1例,均经对症治疗后好转。结论胃肠道来源肺转移瘤,肺内病灶5个以下,最大直径不超过3cm,CT导向下125I粒子植入治疗,创伤小,并发症发生率低,近期效果好。 展开更多
关键词 ^125^Ⅰ粒子 植入 胃肠道来源 肺转移瘤
下载PDF
复合^(125)I粒子植入技术联合TACE治疗肝癌合并门静脉癌栓 被引量:8
18
作者 王万胜 王晨 +7 位作者 沈健 任葆胜 印于 杨俊 唐浩桓 黄鹏 朱晓黎 倪才方 《介入放射学杂志》 CSCD 北大核心 2021年第7期680-686,共7页
目的评估复合^(125)I粒子植入技术(^(125)I粒子螺旋系统序贯肿瘤同侧分支癌栓粒子植入术)联合TACE治疗肝细胞癌(HCC)合并程氏Ⅲ型门静脉癌栓(PVTT)的安全性及有效性。方法对24例HCC合并Ⅲ型PVTT患者行门静脉主干内^(125)I粒子螺旋系统... 目的评估复合^(125)I粒子植入技术(^(125)I粒子螺旋系统序贯肿瘤同侧分支癌栓粒子植入术)联合TACE治疗肝细胞癌(HCC)合并程氏Ⅲ型门静脉癌栓(PVTT)的安全性及有效性。方法对24例HCC合并Ⅲ型PVTT患者行门静脉主干内^(125)I粒子螺旋系统植入术,随后同期行TACE治疗;7~10 d后继行肿瘤同侧分支癌栓内^(125)I粒子植入术。每6~8周行CT增强随访,并按需行再次TACE治疗。统计分析患者并发症、治疗反应率及总生存期。结果所有患者均未发生3级以上严重并发症。门静脉主干癌栓(MPVTT)的客观反应率(ORR)与疾病控制率(DCR)分别为54.2%及87.5%;肝内病变的ORR及DCR分别为29.2%及37.5%。患者中位生存期为(9.5±1.4)(95%CI,6.7~12.3)个月。结论复合^(125)I粒子植入技术联合TACE治疗HCC合并Ⅲ型PVTT是安全可行的,该模式有望进一步改善此类患者预后。 展开更多
关键词 肝细胞癌 门静脉癌栓 ^^(125)I粒子螺旋系统 ^复合^(125)I粒子植入技术 血管内近程放疗 经动脉化疗栓塞术
下载PDF
放射性^(125)I粒子组织间植入治疗软组织肿瘤 被引量:9
19
作者 朱丽红 王俊杰 +7 位作者 袁惠书 冉维强 刘江平 田素清 李金娜 姜伟娟 姜玉良 王皓 《中国微创外科杂志》 CSCD 2008年第3期246-248,共3页
目的评价放射性125I粒子组织间永久性植入治疗软组织肿瘤的疗效和安全性。方法对12例软组织肿瘤共15个病灶(2个原发灶,13个局部复发或转移灶)行125I粒子永久性植入治疗。单个病灶植入粒子60颗(7~80颗),粒子活度0.6mCi(0.5~0.8mCi),肿瘤... 目的评价放射性125I粒子组织间永久性植入治疗软组织肿瘤的疗效和安全性。方法对12例软组织肿瘤共15个病灶(2个原发灶,13个局部复发或转移灶)行125I粒子永久性植入治疗。单个病灶植入粒子60颗(7~80颗),粒子活度0.6mCi(0.5~0.8mCi),肿瘤匹配周边剂量(MPD)140~160Gy。术后行质量验证。2个病灶质量验证不满意加行补充外照射,剂量为30、60Gy,分次剂量2.0Gy。结果中位随访时间17个月(3~34个月)。疼痛缓解率83%(5/6)。术后2个月实际临床获益率(完全缓解CR+部分缓解PR+疾病稳定SD)为93%(14/15)。1年及2年局部控制率均为83%。1年生存率72.9%,2年生存率62.5%,中位生存时间32个月。3例远处转移。5例死亡:1例死于肺转移,4例死于全身多器官衰竭。1例植入粒子后皮肤破溃未愈合,其他患者未出现明显的毒副作用。结论放射性125I粒子植入术单独或联合外照射治疗软组织肿瘤尤其是复发和转移性软组织肿瘤有效,方法简单、易行、微创、安全。 展开更多
关键词 软组织肿瘤 ^放射性^(125)I粒子 组织间种植
下载PDF
放射性^(125)I粒子组织间植入或联合放化疗治疗复发直肠癌 被引量:11
20
作者 王俊杰 袁惠书 +4 位作者 刘江平 姜伟娟 李金娜 姜玉良 田素青 《中国微创外科杂志》 CSCD 2005年第7期522-524,共3页
目的探讨超声或CT引导下放射性125I粒子组织间植入治疗复发直肠癌的技术可行性、近期疗效和副反应。方法15例直肠癌术后盆腔复发患者,女4例,男11例。硬膜外麻醉,2例经阴道超声引导,13例CT引导,行放射性125I粒子植入术。肿瘤匹配周边剂量... 目的探讨超声或CT引导下放射性125I粒子组织间植入治疗复发直肠癌的技术可行性、近期疗效和副反应。方法15例直肠癌术后盆腔复发患者,女4例,男11例。硬膜外麻醉,2例经阴道超声引导,13例CT引导,行放射性125I粒子植入术。肿瘤匹配周边剂量为90~110Gy,每颗粒子活度为0.50~0.70mCi,植入33~70颗。术后24~48h拍胸、盆腔X线片了解粒子是否发生移位。术后6例加三维适形放疗,4~6野/次,200~300cGy/次,5次/周,总剂量为4500~5000cGy,间隔4周。2例粒子治疗后加草酸铂、5-氟尿嘧啶和四氢叶酸化疗1个周期,随访3~15个月,根据CT扫描结果判断肿瘤大小。结果术后平均7天疼痛缓解,其中12例完全缓解,2例部分缓解,1例无变化,有效率93%(14/15)。9例肿瘤完全缓解,2例部分缓解,4例局部进展,局部控制率73%(11/15)。2例术后6个月和12个月时死于肺转移。1例1颗粒子移位至盆壁,随访12个月无症状。无治疗相关并发症和副作用发生。结论经超声或CT引导放射性125I粒子植入治疗复发直肠癌具有安全、微创、并发症发生率低和疗效肯定等优势,粒子治疗后应配合外放疗和全身化疗,有望进一步提高疗效。 展开更多
关键词 ^^125Ⅰ粒子植入 复发直肠癌
下载PDF
上一页 1 2 8 下一页 到第
使用帮助 返回顶部